IRWD
What one share of Ironwood Pharmaceuticals holds
Pharmaceutical Preparations
We are a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. We are focused on the development and commercialization of innovative product opportunities in areas of significant unmet need, leveraging our demonstrated expertise and capabilities in GI and rare diseases.
Ironwood Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $2.39 |
|---|---|
| Profit | $0.80 |
| Cash and investments | $0.48 |
| Debt | $1.21 |
| Book value | −$0.98 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | $1.89 | −$0.56 | $0.03 | −$0.21 | — | $0.46 |
| 2017 | $2.00 | −$0.78 | $0.02 | −$0.69 | — | $0.07 |
| 2018 | $2.27 | −$1.85 | $0.00 | −$0.47 | — | −$1.27 |
| 2019 | $2.75 | $0.14 | $0.05 | $0.02 | — | −$0.59 |
| 2020 | $2.42 | $0.66 | $0.01 | $1.04 | — | $0.39 |
| 2021 | $2.52 | $3.21 | $0.00 | $1.59 | — | $3.74 |
| 2022 | $2.20 | $0.96 | $0.00 | $1.47 | — | $4.24 |
| 2023 | $2.85 | −$6.45 | $0.00 | $1.18 | — | −$2.21 |
| 2024 | $2.20 | $0.01 | $0.00 | $0.65 | — | −$1.88 |
| 2025 | $1.82 | $0.15 | $0.00 | $0.78 | — | −$1.61 |